These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 769956)

  • 1. High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma.
    Piver MS; Barlow JJ; Chung WS
    Cancer Chemother Rep; 1975; 59(6):1157-8. PubMed ID: 769956
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endoxan in ovarian cancer].
    Campodónico I; Soldati A; Rodríguez A
    Rev Chil Obstet Ginecol; 1974; 39(3):87-9. PubMed ID: 4620179
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of adenocarcinoma with combinations of cyclopjosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
    Tucker WG; Talley RW; Lane M; Bonnet JD
    Cancer Chemother Rep; 1975; 59(2 Pt 1):425-7. PubMed ID: 1097101
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
    Beck RE; Boyes DA
    Can Med Assoc J; 1968 Mar; 98(11):539-41. PubMed ID: 5647240
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
    Piver MS; Barlow JJ; Bhattacharya M
    Cancer Treat Rep; 1979 Feb; 63(2):265-7. PubMed ID: 376133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
    Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
    Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide in the treatment of ovarian cancer.
    Decker DG; Mussey E; Malkasian GD; Johnson CE
    Clin Obstet Gynecol; 1968 Jun; 11(2):382-400. PubMed ID: 4879372
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P; Nolte S; Shahin MS
    Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cytostatic activities of cytembena and cyclophosphamide during short-term administration to women with gynaecological carcinoma.
    Skoda V; Jandová A; Novotná J
    Neoplasma; 1970; 17(2):175-81. PubMed ID: 5269150
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
    Decker DG; Malkasian GD; Mussey E; Johnson CE
    Am J Obstet Gynecol; 1967 Mar; 97(5):656-65. PubMed ID: 4959953
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.
    Mangioni C; Bolis G; Natale N; Morasca L
    Eur J Cancer (1965); 1976 May; 12(5):353-6. PubMed ID: 954793
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer.
    Barlow JJ; Piver MS
    Cancer Treat Rep; 1976 May; 60(5):527-33. PubMed ID: 1086714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial.
    Burn JI; Cooke WM
    Cancer Chemother Rep; 1974; 58(6):867-70. PubMed ID: 4615786
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tissue reaction in ovarian carcinoma after cyclophosphamide (Endoxan) therapy].
    Engeler V; Hanski W
    Pathol Microbiol (Basel); 1969; 33(3):153-60. PubMed ID: 5350583
    [No Abstract]   [Full Text] [Related]  

  • 19. [High-dose chemotherapy in ovarian adenocarcinoma].
    Lotz JP; Lhommé C; Pautier P; Couteau C; Gligorov J; Alexandre J; Selle F; Izrael V; Maraninchi D; Viens P
    Bull Cancer; 2000 Jan; 87(1):63-9. PubMed ID: 10673633
    [No Abstract]   [Full Text] [Related]  

  • 20. Cis-platin-Mecy as salvage chemotherapy in recurrent advanced ovarian carcinoma.
    Belli M; Colantuoni G; Di Iorio B
    G Ital Oncol; 1989; 9(1):31-3. PubMed ID: 2785083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.